All In MedTech

FDA Clearance Tracker · P010029-S025

EUFLEXXA (1% Sodium Hyaluronate)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 28, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 28, 2017

Approved

Time to decision

191 days

Received Jun 20, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P010029-S025
Device name
EUFLEXXA (1% Sodium Hyaluronate)
Applicant location
Parsippany, NJ
Received
Jun 20, 2017
Decided
Dec 28, 2017
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P010029

Device type

Device class
Class III

Every decision under product code MOZ

FDA's approval statement

As written in FDA's record.

Approval for BTG (Ferring) to manufacture, package and release Euflexxa at both the BTG (Ferring) and Lifecore facilities.

Source documents

Other decisions for Ferring Pharmaceuticals, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.